Key Details
Price
$1.08Last Dividend
$0.10TTM Dividend Yield
9.26%Annual ROE
-38.76%Beta
0.40Events Calendar
Next earnings date:
Dec 13, 2024Recent quarterly earnings:
June 13, 2024Recent annual earnings:
Oct 14, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
Nov 15, 2024Next split:
N/ARecent split:
Oct 21, 2004Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Enzo Biochem's overall topline benefits from revenue growth in the majority of its geographic regions.
FARMINGDALE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal fourth quarter ended July 31, 2024 and the fiscal year ended July 31, 2024. The Company also announced that its board of directors had authorized a cash dividend of $0.10 per share of its common stock.
Enzo Biochem will pay $4.5 million to settle claims it failed to adequately safeguard personal and private health information of its patients, New York Attorney General Letitia James said on Tuedsay.
Enzo Biochem shareholders frustrated with lack of capital returns following Clinical Labs sale to Labcorp Holdings. Stock trading near historic lows, but potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Valuation potential of $2.00-3.22/share with $35m net cash and $75-120m business value, pending resolution of legal issues and potential share buybacks.
Discover why Zacks rates Enzo Biochem as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ENZ's notable revenue growth and financial health amid market challenges.
Enzo Biochem's (ENZ) overall topline benefits from revenue growth in the majority of its geographic regions.
FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024.
Enzo Biochem is a microcap company with a $30 million revenue run-rate Life Sciences business and $78-$85 million in cash. The company is likely being prepared for sale, with interest from potential acquirers and activists controlling 30% of voting shares. Enzo's focus on generating positive cash flow and enhancing shareholder value could lead to significant improvement in Life Sciences results.
FARMINGDALE, NY, April 24, 2023 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the sale (the “Asset Sale”) of substantially all the assets and assignment of certain liabilities of its clinical laboratory business to Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”) and adopt the Asset Purchase Agreement, dated as of March 16, 2023 (as such agreement may be amended from time to time, the “Asset Purchase Agreement”), by and among the Company, Enzo Clinical Labs, Inc., a New York corporation and Labcorp will be held on May 22, 2023 at 9:00 a.m. Eastern Time.
FAQ
- What is the primary business of Enzo Biochem?
- What is the ticker symbol for Enzo Biochem?
- Does Enzo Biochem pay dividends?
- What sector is Enzo Biochem in?
- What industry is Enzo Biochem in?
- What country is Enzo Biochem based in?
- When did Enzo Biochem go public?
- Is Enzo Biochem in the S&P 500?
- Is Enzo Biochem in the NASDAQ 100?
- Is Enzo Biochem in the Dow Jones?
- When was Enzo Biochem's last earnings report?
- When does Enzo Biochem report earnings?